29 mayo 2015
The first clinical study of the anticancer effects of the novel agent entolimod are now available. Findings confirm preclinical evidence that the agent, which is derived from salmonella flagellin, is worthy of further investigation as treatment for some of the most common and most resilient solid-tumor cancers.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/8m7cTBfRrrk/150529100954.htm
